

Financial Year 2011 Media and Analysts Meeting

March 15, 2012

2011 Leveraging the Group's Position



Safe Harbour Statement

The information made available in this conference may include forward-looking statements that reflect the intentions, beliefs or current expectations and projections of COLTENE Holding AG about the future results of operations, financial condition, liquidity, performance and similar circumstances. Such statements are made on the basis of assumptions and expectations which may prove to be erroneous, although COLTENE Holding AG believes them to be reasonable at this time.



2011 Review

Erwin Locher, CEO ad interim and Delegate of the Board



COLTENE at a Glance

Global dental specialist

Highly recognized global brand for chairside dental consumables

Swiss based small cap with worldwide sales through dental distributors and 175 sales representatives

Global dental specialist

Development and Operations in Europe, North America and Brazil

Strong emerging market position with 26% of total sales in 2011



Comprehensive Product Portfolio Globally marketed through sales partner



Adhesives/ Restoratives



Endodotics



Prosthetics

- Focusing on innovative, aesthetically-pleasing filing materials and high-precision mechanical instruments
- Comprehensive R&D portfolio with iterative product improvement in all major segments



Rotary instruments



Treatement auxiliaries



Hygiene



Achievements 2011

Leveraging the Group's position

- Revenue of CHF 146.1 million; reflecting organic growth of 1.6% at constant exchange rates (CER)
 - Significant currency fluctuation and inventory reductions at dealers
 - Gain of market shares in a challenging environment
- Emerging markets with strong revenue growth of 25.9%
 - 8.4% organic growth at CER
 - Concluded transition of Vigodent in Brazil
- Operating profit (EBIT) down by 33.6% to CHF 12.3 million
- Free cash flow at CHF 9.9 million
- Strong equity ratio of 63.1%
- Proposed distribution of CHF 1.10 from past capital contributions



Dental Consumables Market

Attractive Growth Perspectives

- Increasing importance of oral hygiene and aesthetic dentistry
 - Global demographic and economic trends
 - Social/lifestyle factors
- Relative stability of dental consumables market
 - Shared costs between patients and public health insurance
 - Less dependent on economic cycle compared to general dental market

Dental consumable		Total	Increase	Increase
markets chairside		Market	over 2010	Coltene
United States	USD	3'417.6	3.8%	4.4%
Germany	EUR	891.0	2.0%	2.7%
Brazil	BRL	350.6	7.0%	9.0%



Management Actions 2011


Transition of Brazilian operations and launch of new products

- Reorganization of Vigodent concluded
 - Brazilian subsidiary allows further market penetration
 - Important hub for supplying products to Mercosur markets
- Focus on organic growth
 - Focusing on dental consumables
 - Development of innovative products with sustainable customer benefits
 - Productivity gains
- Enhancing the brand name recognition
 - Tightening customer relations and dialogue to existing and new client groups
 - Strengthening and expanding multi-layer marketing organization



Regional Breakdown

Strong organic growth in emerging markets



1	Switzerland	2%
2	Germany, Austria	14%
3	Great Britain, Ireland	5%
4	France	4%
5	Other Europe	14%
6	Russia and other CIS	3%
7	Middle East and Africa	4%
8	North America	31%
9	Brazil	8%
10	Other South America	5%
11	China	2%
12	India	1%
13	Other Far East, Oceania	7%

- Good growth rates in local currencies, but translation into Swiss francs weighs on results
- 26.5% of Group sales in emerging economies
- North America showed slight decline in local currencies due to inventory reductions at dealers
- Divergent development in European countries



Dynamic Brazilian MarketVigodent fully consolidated


- Leverage COLTENE's position in Brazil
 - Intensified dialogue with key opinion leaders
 - Extended dental school programs
- Shift of local Vigodent offering to COLTENE products with higher margins
 - Migration of local brands to COLTENE "originals" higher perceived embedded technology and bibliographical reference)



- Concluded reorganization of Vigodent
 - Excellent platform to exploit the attractive opportunities of the Brazilian market
 - Hub for supplying products to Mercosur markets



Breakdown by Product Groups Increasing demand for aesthetic dentistry



1	Restoration	23%
2	Impression	21%
3	Endodontics	16%
4	Hygiene and Surgical	11%
5	Units/Accessories	7%
6	Rotary	7%
7	Laboratory and	
	Miscellaneous	15%

- Sales growth resulted primarily from restoration, impression, and hygiene materials
- Sales in endodontics were below expectations due to delayed launch in the U.S.
- Successful entry into the veneer market at IDS dental show in cologne, Germany in March 2011



Innovative Products (I) COMPONEER™



- New composite veneer system
- Designed for simple, safe, and time-saving restorations of front teeth
- Providing patients with a natural and aesthetic smile
- Unique one sessiontreatment



Innovative Products (II)

HyFlex™ Controlled Memory NiTi files



- New endodontic files
- Adjust to the given root canal anatomies
- Reduce the risks of displacement or perforation of the root canal



Operational Excellence Constant improvements

- Continued roll-out of group-wide ERP system
 - 2010: Introduction in Switzerland in 2010
 - 2011: Extension on German operations
 - 2012: Inclusion of COLTENE sites in the US
- Improved exchange of information and know-how
- Further balanced allocation of group functions to specific currency areas
 - To offset the tectonic shifts in the global currency landscape
 - As a initial measure, move of logistics from products manufactured in Altstätten, Switzerland to Langenau, Germany



Proposals to AGM

- All members of the Board of Directors are available for re-election
- Election of Ernst & Young AG as auditors
- Distribution of CHF 1.10 from past capital contributions



2011 Financial Review

Dr. Hans Grüter, CFO



Financial Summary Solid performance despite headwinds

Top-line performance

- Expansion of 7.8% CER
- Decrease of 4.9% in reported CHF
- 1.6% organic growth CER

Operational profit

- Affected by translation effects and by the restructuring of Vigodent
- EBIT margin down to 8.4%

Healthy free cash flow

- Cash flow from operations above PY
- Increased investments

Solidly financed

- High equity ratio of 63% maintained
- Unused credit line of CHF 63 million

Headwinds

Strong Swiss Franc

1 USD: 1.04 -> 0.89

1 EUR: 1.38 -> 1.23

- Dealer's inventory reduction
- Vigodent's restructuring



Income StatementSolid performance


In CHF million	2011	%	2010	%	% YoY
Net Sales	146.1	100.0%	153.6	100.0%	-4.9%
Material expenses*	-44.5	-30.5%	-44.1	-28.7%	0.9%
Operating expenses	-84.4	-57.8%	-86.3	-56.2%	-2.2%
Depr. & Amor.	-4.9	-3.4%	-4.8	-3.1%	2.1%
EBIT	12.3	8.4%	18.4	12.0%	-33.6%
Financial result**	-3.3	-2.3%	-5.1	-3.3%	-35.3%
Tax expenses	-3.0	-2.1%	-4.0	-2.6%	-25.0%
Profit for the period	6.0	4.1%	9.3	6.1%	-35.5%


^{*:} Raw materials used, changes in inventory and work performed capitalized

^{**: 2010} including profit from discontinued operations



Net Sales DevelopmentSustained growth in emerging markets





Comments

- Reported decrease of 4.9% to CHF 146.1 million
- •Increase of 7.8% to CHF 165.5 million CER
- •1.6% organic growth CER
- Vigodent contributed CHF 10.5 million or 7.2% of total sales
- Consummated dealer's inventory reduction of approx. CHF 3.5 million

- Small increase in Europe from CHF 63.8 million to CHF 64.0 million CER
- Small decrease in North America from CHF 54.2 million to CHF 53.4 million CER (dealer's inventory reductions)
- Emerging markets organic growth of 8.4% CER



EBIT Margin

Affected by currency fluctuations and Vigodent

	2010	2011	Fx	Vigodent**	2011
In CHF million	Result	Result	Adjustments	Adjustments	Adjusted
Net Sales	153.6	146.1	19.4	-9.5	156.0
Material					
expenses*	-44.1	-44.5	-6.8	3.6	-47.7
Operating					
expenses	-86.3	-84.4	-8.9	7.0	-86.3
Depreciation &					
amortisation	-4.8	-4.9	-0.5	0.4	-5.0
EBIT	18.4	12.3	3.2	1.5	17.0
In % of net sales	12.0%	8.4%			10.9%

^{*:} Raw materials used, changes in inventory and work performed capitalized

- Main impact due to currency translation (CHF 3.2 million) and Vigodent (CHF 1.5 million)
- Adjusted EBIT margin of 10.9% comparable with 12.0% of prior year
- Operating expenses on same level as prior year
- Vigodent's EBIT in 2011 was CHF -2.2 million

^{**:} Delta 2010 to 2011



Financial Expenses and Taxes


In CHF million	2011	2010	% YoY
EBIT	12.3	18.4	-33.6%
Interest income and expenses	-1.2	-0.7	
Exchange rate differences	-2.1	-1.9	
Gain on call option associates	0.0	1.2	
Share of loss of associates	0.0	-0.8	
Impairment on associates	0.0	-3.0	
Net profit before tax	9.0	13.2	-31.8%
Tax expenses	-3.0	-4.0	
Net profit continuing			
operations	6.0	9.2	-34.8%
Discontinued operations	0.0	0.1	
Profit for the period	6.0	9.3	-35.5%

- Higher interest expenses due to 12 months consolidation of Vigodent (PY 2 months) and higher average debt
- Exchange rate difference and other expenses increase from CHF 1.9 million to CHF 2.1 million
- Financial result CHF
 -3.3 million compared to
 CHF -5.2 million in 2010
- Effective tax rate with 33.5% on a high level due to Vigodent's losses which were not capitalized in 2011



Cash Flow Statement

Free cash flow remains on a healthy level



- NWC changes compensated lower net profit and non-cash items leading to a higher cash flow from operations in 2011
- Investments in equipment CHF 1.6 million higher than PY
- Investments in intangibles, mainly SAP
- Roll-out in Switzerland and Germany successfully completed
- Roll-out in the US planned for summer 2012
- 2011 investments on the level of depreciation & amortization expenses



Balance Sheet StructureSolidly financed

31.12.11	31.12.10	Δ
3.1	4.1	-1.0
34.1	37.0	-2.9
29.9	32.5	-2.5
30.5	31.7	-1.1
52.2	53.4	-1.2
149.9	158.7	-8.8
31.12.11	31.12.10	Δ
17.4	19.7	-2.3
30.2	34.1	-3.9
7.7	7.0	0.7
94.6	97.8	-3.3
149.9	158.7	-8.8
	3.1 34.1 29.9 30.5 52.2 149.9 31.12.11 17.4 30.2 7.7 94.6	3.1 4.1 37.0 29.9 32.5 30.5 31.7 52.2 53.4 149.9 158.7 31.12.10 17.4 19.7 30.2 34.1 7.7 7.0 94.6 97.8

- Currency impact on the total balance sheet rather small (CHF 1.9 million)
- Reduced DSO lead to lower receivables
- Some progress made in inventory reduction; further potential to be realized
- Bank loans reduces by CHF 3.9 million to CHF 30.2 million
- Unused uncommitted credit lines of CHF 63 million
- Equity ratio with 63% remained on a high level



Growth Drivers and Outlook

Erwin Locher, CEO ad interim and Delegate of the Board



Major Shifts From 2006 - 2013

Ascension to a leading player with global footprint

Leveraging Position

Global Presence

Activity Focus

Medisize Listing

- Sale of Medical Business
- Focus on Dental Consumables Market
- Grow core activites by acquisition, reach and innovation
- Expand dental portfolio (rotary)
- Bulid emerging markets

- Set-up in India and China
- Acquisition of Vigodent in Brazil
- Focus on value-based core competencies
- Leverage global sales presence and group locations
- Focus on management processes and execution



Growth Drivers (I)

Leverage brand with innovative solutions




- For example with
 - COMPONEER™ in aesthetic dentistry, or
 - HyFlex[™] in endodontics
- Innovation driven to improve the Customer value proposition
 - Outcome
 - Ease of use
 - Differentiation for the dentist towards his patient
 - Affordability



Growth Drivers (II)

Leverage of emerging market network






- For example with
 - Vigodent in Brazil
 - Established sales networks in India and China
- Vigodent's local brands and COLTENE's global products allow for new market position and significant future growth
- Intensified marketing and sales activities in Asia with a special focus on India and China



Growth Drivers (III)

Leverage of sales and marketing organization



- For example with
 - Multi-layer marketing approach
 - Focused sales efforts
- The Coltene Sales
 organization promotes new or
 focus products directly to the
 dentist, especially to key
 opinion leaders
- The full portfolio of Coltene products is sold and distributed by global, regional or local distribution partners



Growth Drivers (IV)

Leverage of portfolio and lean manufacturing capabilities



- For example with
 - OEM
 - Private label volumes
- COLTENE owns highly automated manufacturing centers for various product groups
- Defined proactive strategy to participate in the growth potential of private label products



Outlook

Further leveraging the Group's position

- Management expects in 2012
 - + Growing dental consumables markets in most areas of the world
 - + Increased sales in traditional and emerging markets thanks to newly launched products and promotions
 - + Positive effects from operational improvements
 - Continued strength of the Swiss Franc
 - Continued and planned inventory reductions at dealers
- COLTENE well positioned to exploit growth potential
 - Well positioned in both traditional and emerging markets
 - Core competencies in the areas of restoration, aesthetics and endodontics
 - Wide and versatile product range based on solid expertise in key state-of-the-art technologies
 - Broadly based organizational structure



Thank you for your Attention

